How to use the speech recognition tool?
NCT03746522
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl
Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity.
Type: Interventional
Status of the trial: Completed
Orphan Drug Recognition: NA
Inclusion
- Opening Date: 2020-02-17
- Closing Date: 2020-03-21
Criteria
Children: Yes
Adults: Yes
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
Workgroups
Retinal Rare Eye Diseases (WG1)